Tobacco/Drug Use Cardiac Athlete Risk Multiplier Calculator

Clinical calculation support · Verify results before clinical use

Substance Exposure & Athlete Cardiovascular Review

Record relevant exposure and resting heart rate to support a structured clinical discussion.

Clinical review

Patient and athlete profile

Record after adequate rest; interpret in context of training status, symptoms, and medications.
Examples include chest pain, syncope/presyncope, unexplained dyspnea, or sustained palpitations.

Tobacco and substance exposure

Exposure duration alone does not establish dose, frequency, route, recency, or an individual cardiovascular risk estimate.

Important: no validated risk multiplier is available

The percentage-per-year factors and substance multipliers in the original code are not supported by a validated clinical prediction model or the cited sports-cardiology guideline. A numerical “times baseline” result could therefore imply a level of precision that the evidence does not establish.

This tool does not calculate absolute or relative cardiovascular event risk and does not determine fitness to compete or return-to-play clearance.

Clinical review summary

Clinical context

Substance exposure may be relevant when evaluating cardiovascular symptoms, arrhythmia, ischemia, blood pressure, and participation in sport. The type of substance, amount, route, frequency, time since last use, co-exposures, underlying disease, and clinical findings all affect assessment.

Practical assessment points

  • Clarify substance, dose or amount, frequency, route, last use, and whether multiple substances are involved.
  • Assess symptoms, personal and family cardiac history, medications, examination findings, and conventional cardiovascular risk factors.
  • Investigate concerning symptoms or abnormal findings according to clinical judgement and relevant sports-cardiology guidance.
  • Do not use resting heart rate or exposure duration alone to clear an athlete for high-intensity training or competition.

When urgent assessment is needed

Chest pain, syncope, severe breathlessness, sustained palpitations, or acute symptoms after stimulant or other substance use warrant prompt medical assessment; emergency symptoms require emergency services.

Evidence and limitations

Evidence supports considering substance exposure in cardiovascular evaluation, but it does not validate the original fixed multipliers or the proposed mild/moderate/high thresholds. Risk should be assessed clinically rather than inferred from this tool's arithmetic.

Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal. 2021;42(1):17–96. DOI: 10.1093/eurheartj/ehaa605.
Page RL II, Allen LA, Kloner RA, et al. Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2020;142:e131–e152. DOI: 10.1161/CIR.0000000000000883.
Clinical disclaimer: This form is an exposure-history aid, not a validated cardiovascular risk score, diagnostic tool, or return-to-play decision rule. It does not replace clinician assessment or applicable guidelines. Data are processed in the page's browser by this script; this template does not submit the entered fields to the server.